IL9 and hepatocellular carcinoma: Importantly, serum IL-9 level was robustly increased in HCC patients post therapy (146.2 ± 17.43 pg/mL vs 95.27 ± 12.53 pg/mL, P<0.0001, paired t test, Figure 2D).